DK2231193T3 - Lægemiddelleveringssystem til administration af et vandopløseligt, kationisk og amfifilt farmaceutisk aktivt stof - Google Patents
Lægemiddelleveringssystem til administration af et vandopløseligt, kationisk og amfifilt farmaceutisk aktivt stof Download PDFInfo
- Publication number
- DK2231193T3 DK2231193T3 DK08863195.7T DK08863195T DK2231193T3 DK 2231193 T3 DK2231193 T3 DK 2231193T3 DK 08863195 T DK08863195 T DK 08863195T DK 2231193 T3 DK2231193 T3 DK 2231193T3
- Authority
- DK
- Denmark
- Prior art keywords
- methyl ester
- delivery system
- sodium salt
- pharmaceutically active
- drug delivery
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (11)
1. Lægemiddelleveringssystem til administration af mindst ét farmaceutisk aktivt stof, der er en kationisk amfifil i sig selv og mindst ét andet farmaceutisk aktivt stof med en opløselighed per se i vand på mindre end 100 pg/ml, hvilke farmaceutisk aktive stoffer er til stede i lægemiddelleveringssystemet i partikler af et kompleks mellem nævnte farmaceutisk aktive stoffer og et natriumsalt af methylesteren af N-alle-trans-retinoylcysteinsyre, et natriumsalt af methylester af N-13-cis-retinoylcysteinsyre, eller en kombination deraf, hvor nævnte partikler af nævnte kompleks har en effektiv gennemsnitlig partikelstørrelse på mindre end 100 nm, hvor - partiklerne af nævnte kompleks er i alt væsentligt amorfe; - partiklerne af nævnte kompleks er indespærret i nanopartikler dannet af et natriumsalt af methylesteren af N-alle-trans-retinoylcysteinsyre, natriumsalt af methylester af N-13-cis-retinoylcysteinsyre, eller en kombination deraf; og - vægt-til-vægt-forholdet af nævnte natriumsalt af methylester af N-alle-trans-retinoylcysteinsyre, natriumsalt af methylester af N-13-cis-retinoylcysteinsyre, eller kombination deraf, til vægten af nævnte kompleks er i området fra 0,5:1 til 20:1.
2. Lægemiddelleveringssystem ifølge krav 1, kendetegnet ved, at nævnte farmaceutisk aktive stof har en opløselighed per se i vand på mindst 4 mg/ml, og at nævnte kompleks er et ikke-kovalent kompleks med en opløselighed i vand på under 0,1 mg/ml.
3. Lægemiddelleveringssystem ifølge krav 1 eller 2, kendetegnet ved, at nævnte kompleks har en effektiv gennemsnitlig partikelstørrelse på mindre end omkring 50 nm.
4. Lægemiddelleveringssystem ifølge et hvilket som helst af de foregående kravene, kendetegnet ved, at vægt-til-vægt-forholdet af nævnte natriumsalt af methylesteren af N-alle-trans-retinoylcysteinsyre, natriumsalt af methylesteren af N-13-cis-retinoylcysteinsyre, eller kombination deraf, til vægten af nævnte kompleks er i området fra 1:1 til 10:1.
5. Lægemiddelleveringssystem ifølge et hvilket som helst af de foregående krav, kendetegnet ved, at mindst ét af nævnte farmaceutisk aktive stoffer er en cytotoksisk eller en cytostatisk forbindelse i hvilken nævnte cytotoksiske eller en cytostatisk forbindelse er en protoneret form af doxorubicin, mitoxantron, epirubicin, daunorubicin, idarubicin, topotecan, irinotecan, vinblastin, vineristin, vinorelbin, amsacrin, procarbazin, mechlorethamin, eller en kombination deraf.
6. Lægemiddelleveringssystem ifølge et hvilket som helst af de foregående krav, kendetegnet ved, at nævnte andet farmaceutisk aktive stof er en cytotoksisk eller cytostatisk forbindelse.
7. Lægemiddelleveringssystem ifølge krav 6, kendetegnet ved, at nævnte cytotoksiske eller cytostatiske forbindelse er en taxan, i hvilken nævnte taxan er valgt blandt paclitaxel, docetaxel, og derivater deraf.
8. Lægemiddelleveringssystem ifølge krav 1, kendetegnet ved, at nævnte mindst ene farmaceutisk aktive stof og nævnte andet farmaceutisk aktive stof er cytotoksiske eller cytostatiske forbindelser, i hvilke nævnte mindst ene farmaceutisk aktive stof er en protoneret form af doxorubicin, mitoxantron, epirubicin, daunorubicin, idarubicin, topotecan, irinotecan, vinblastin, vineristin, vinorelbin, amsacrin, procarbazin, mechlorethamin, eller en kombination deraf.
9. Lægemiddelleveringssystem ifølge krav 1, kendetegnet ved, at nævnte andet farmaceutisk aktive stof er en taxan, hvor nævnte taxan er valgt blandt paclitaxel, docetaxel, og derivater deraf.
10. Lægemiddelleveringssystem ifølge et hvilket som helst af kravene 1-9 til anvendelse i behandlingen af cancer.
11. Farmaceutisk sammensætning omfattende en farmaceutisk acceptabel bærer og lægemiddelleveringssystemet ifølge et hvilket som helst af kravene 1-10.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/SE2007/001128 WO2009078755A1 (en) | 2007-12-19 | 2007-12-19 | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
PCT/SE2008/051517 WO2009078804A1 (en) | 2007-12-19 | 2008-12-18 | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2231193T3 true DK2231193T3 (da) | 2018-10-22 |
Family
ID=40795733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08863195.7T DK2231193T3 (da) | 2007-12-19 | 2008-12-18 | Lægemiddelleveringssystem til administration af et vandopløseligt, kationisk og amfifilt farmaceutisk aktivt stof |
Country Status (23)
Country | Link |
---|---|
US (1) | US8324274B2 (da) |
EP (1) | EP2231193B1 (da) |
JP (1) | JP5466174B2 (da) |
KR (1) | KR101616135B1 (da) |
CN (1) | CN101945671B (da) |
AU (1) | AU2008339101B2 (da) |
BR (1) | BRPI0821739B8 (da) |
CA (1) | CA2709268C (da) |
CY (1) | CY1121145T1 (da) |
DK (1) | DK2231193T3 (da) |
EA (1) | EA018559B1 (da) |
ES (1) | ES2689509T3 (da) |
HR (1) | HRP20181517T1 (da) |
HU (1) | HUE039695T2 (da) |
LT (1) | LT2231193T (da) |
MX (1) | MX2010006906A (da) |
MY (1) | MY150820A (da) |
NZ (1) | NZ586858A (da) |
PL (1) | PL2231193T3 (da) |
PT (1) | PT2231193T (da) |
SI (1) | SI2231193T1 (da) |
WO (2) | WO2009078755A1 (da) |
ZA (1) | ZA201004992B (da) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009078756A1 (en) | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
WO2009078754A1 (en) * | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
CN112321465B (zh) * | 2019-07-18 | 2023-06-06 | 上海现代药物制剂工程研究中心有限公司 | 一种含苯基化合物、其中间体、制备方法及应用 |
CN112239418B (zh) * | 2019-07-18 | 2023-07-07 | 上海现代药物制剂工程研究中心有限公司 | 视黄醇类化合物及其钠盐的制备方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6197809B1 (en) * | 1998-12-23 | 2001-03-06 | Ardenia Investments Ltd. | Compounds for the treatment of cancer |
AU766256B2 (en) * | 1999-03-11 | 2003-10-09 | Ardenia Investments Ltd. | New compounds for the treatment of cancer |
US6656504B1 (en) | 1999-09-09 | 2003-12-02 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
SE0101702D0 (sv) * | 2001-05-15 | 2001-05-15 | Ardenia Investments Ltd | Novel potentiating compounds |
KR100566911B1 (ko) * | 2001-06-25 | 2006-04-03 | 주식회사 삼양사 | 약물 전달체용 음이온기-함유 양친성 블록 공중합체 및 그의 양이온성 약물과의 복합체 |
US20050249786A1 (en) * | 2001-09-28 | 2005-11-10 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds |
US20050191359A1 (en) * | 2001-09-28 | 2005-09-01 | Solubest Ltd. | Water soluble nanoparticles and method for their production |
JP2004010479A (ja) * | 2002-06-03 | 2004-01-15 | Japan Science & Technology Corp | ブロック共重合体とアンスラサイクリン系抗癌剤を含む新規固型製剤及びその製造法 |
SE0202311D0 (sv) * | 2002-07-23 | 2002-07-23 | Ardenia Investments Ltd | Novel compounds, cytotoxic preparations comprising said compounds, methods of manufacture of said preparations, as well as methods of treatment |
JP2006199590A (ja) * | 2003-09-04 | 2006-08-03 | Nano Career Kk | 水溶性の塩基性薬物内包ナノ粒子含有組成物 |
US20050196343A1 (en) * | 2004-02-27 | 2005-09-08 | Molecular Therapeutics, Inc. | Degradable nanoparticles |
US8945629B2 (en) * | 2004-09-10 | 2015-02-03 | University Of Wyoming | Nanoparticles for cytoplasmic drug delivery to cancer cells |
HUE038768T2 (hu) * | 2005-02-18 | 2018-11-28 | Abraxis Bioscience Llc | Terápiás szerek kombinációi, valamint beadásukra szolgáló módszerek, és kombinációs terápia |
CN101291658B (zh) * | 2005-08-31 | 2014-04-16 | 阿布拉科斯生物科学有限公司 | 用于制备稳定性增加的水难溶性药物的组合物和方法 |
WO2009078756A1 (en) | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
WO2009078754A1 (en) | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
-
2007
- 2007-12-19 WO PCT/SE2007/001128 patent/WO2009078755A1/en active Application Filing
-
2008
- 2008-12-18 ES ES08863195.7T patent/ES2689509T3/es active Active
- 2008-12-18 BR BRPI0821739A patent/BRPI0821739B8/pt active IP Right Grant
- 2008-12-18 CN CN2008801270941A patent/CN101945671B/zh active Active
- 2008-12-18 EP EP08863195.7A patent/EP2231193B1/en active Active
- 2008-12-18 EA EA201070626A patent/EA018559B1/ru unknown
- 2008-12-18 SI SI200831998T patent/SI2231193T1/sl unknown
- 2008-12-18 KR KR1020107015634A patent/KR101616135B1/ko active IP Right Grant
- 2008-12-18 AU AU2008339101A patent/AU2008339101B2/en active Active
- 2008-12-18 JP JP2010539387A patent/JP5466174B2/ja active Active
- 2008-12-18 NZ NZ586858A patent/NZ586858A/en unknown
- 2008-12-18 HU HUE08863195A patent/HUE039695T2/hu unknown
- 2008-12-18 MX MX2010006906A patent/MX2010006906A/es active IP Right Grant
- 2008-12-18 PL PL08863195T patent/PL2231193T3/pl unknown
- 2008-12-18 WO PCT/SE2008/051517 patent/WO2009078804A1/en active Application Filing
- 2008-12-18 US US12/809,265 patent/US8324274B2/en active Active
- 2008-12-18 PT PT08863195T patent/PT2231193T/pt unknown
- 2008-12-18 LT LTEP08863195.7T patent/LT2231193T/lt unknown
- 2008-12-18 CA CA2709268A patent/CA2709268C/en active Active
- 2008-12-18 DK DK08863195.7T patent/DK2231193T3/da active
- 2008-12-18 MY MYPI20102785 patent/MY150820A/en unknown
-
2010
- 2010-07-14 ZA ZA2010/04992A patent/ZA201004992B/en unknown
-
2018
- 2018-09-25 HR HRP20181517TT patent/HRP20181517T1/hr unknown
- 2018-10-03 CY CY20181101023T patent/CY1121145T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2231189B1 (en) | Drug delivery system for administration of poorly water soluble pharmaceutically active substances | |
US20150328234A1 (en) | Bufalin liposome, preparation method therefor and application thereof | |
DK2231193T3 (da) | Lægemiddelleveringssystem til administration af et vandopløseligt, kationisk og amfifilt farmaceutisk aktivt stof | |
JP5466173B2 (ja) | 水溶性、カチオン性および両親媒性の薬学的に活性な物質を投与するためのドラッグ・デリバリー・システム | |
Jiang et al. | Research progress of carrier-free antitumor nanoparticles based on phytochemicals | |
CN108392483A (zh) | 一种紫杉醇联合2-甲氧基雌二醇的白蛋白纳米粒的制备方法及应用 | |
CN111743877A (zh) | 一种紫杉醇拉帕替尼复方纳米结晶及其制备方法 | |
TW201720447A (zh) | 裝載活性成份之奈米粒子、彼等之製法及用途 |